Cinchocaine 1.1% ointment
A local anesthetic of the amide type now generally used for surface anesthesia.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Cinchocaine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Cinchocaine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Cinchocaine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Randomised trials: 1 · 1947–2025
Showing the 50 most relevant studies, sorted by most relevant.
Cook Pt, Michael J. Davies, Keith D. Cronin, et al.
Anaesthesia and Intensive Care, 1986
- Dibucaine
- Anesthesia, Spinal
- Anesthesia, General
D. Brindley, M. Bowley
The Biochemical journal, 1975
Mamdouh R. Rezk, Ahmed S. Fayed, Hoda M. Marzouk, et al.
Journal of The Electrochemical Society, 2017
Oxford English Dictionary, 2023
Aminul Islam, Anika Zafreen, Sadia Islam, et al.
Asian Journal of Chemical Sciences, 2025
Che Jinshan, Sun Mingming, Li Zhipan
Reviews in Analytical Chemistry, 2025
An electrochemical sensor for cinchocaine (CIN) detection was developed based on surface molecular imprinting technology utilizing screen-printed gold electrodes modified with TiO2 nanoparticles and electropolymerized polypyrrole. A novel sensor was developed using a dual-stage methodology, which entailed initial CIN template immobilization and subsequent electrochemical pyrrole polymerization incorporating titanium dioxide nanoscale particles. The sensor exhibited enhanced electroactive surface area (0.075 cm2) and improved electron transfer kinetics (heterogeneous rate constant 8.2 × 10−3 cm·s−1) compared to unmodified electrodes. Under optimized conditions (pH 5.0, 15-min incubation), the sensor demonstrated two linear response ranges from 0.1–10 and 10–100 μM, with a detection limit of 0.035 μM. The sensor showed excellent selectivity against common interferents, including a 100-fold excess of inorganic ions and a 50-fold excess of structurally similar compounds. Analysis of clinical samples yielded excellent recoveries (97.2–102.3%) with relative standard deviations below 4.3%. The simple fabrication process, rapid response time, and minimal sample preparation requirements make this sensor particularly suitable for point-of-care applications.
Abstract licence: CC BY 4.0
Inês C. Farinha, Francisca Cunha Tavares, Emília Faria, et al.
Arquivos de Asmas Alergia e Imunologia, 2024
L. Jones, R. Michell
The Biochemical journal, 1975
R. Sturton, D. Brindley
The Biochemical journal, 1977
Sally E.A. Elashery, Eman Yossri Frag, Ashraf A.E. Sleim
Measurement, 2021
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
1 found
Half-life
Not available
Mechanism
Local anesthetics block both the initiation and conduction of nerve impulses by…
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1798 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:1309946 PMID:21447824 PMID:23085483 PMID:23420830 PMID:25370050 PMID:26279430 PMID:26392562 PMID:26776555
Nav1.5 is the predominant sodium channel expressed in myocardial cells and it is responsible for the initial upstroke of the action potential in cardiac myocytes, thereby initiating the heartbeat .
PMID:11234013 PMID:11804990 PMID:12569159 PMID:1309946
Required for normal electrical conduction including formation of the infranodal ventricular conduction system and normal action potential configuration, as a result of its interaction with XIRP2 (By similarity)
PMID:16760425 PMID:31454269
Calcium-binding is required for the activation of calmodulin .
PMID:16760425 PMID:31454269 PMID:35568036
Among the enzymes to be stimulated by the calmodulin-calcium complex are a number of protein kinases, such as myosin light-chain kinases and calmodulin-dependent protein kinase type II (CaMK2), and phosphatases .
PMID:16760425 PMID:35568036
Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis PMID:16760425
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC D04AB02
ATC S01HA06
ATC S02DA04
ATC N01BB06
ATC C05AD04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cinchocaine
Additional database identifiers
Drugs Product Database (DPD)
9206
Drugs Product Database (DPD)
7053
ChemSpider
2917
BindingDB
48532
ZINC
ZINC000001530939
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10593
GenAtlas
SCN5A
GeneCards
SCN5A
GenBank Gene Database
M77235
GenBank Protein Database
184039
Guide to Pharmacology
582
UniProt Accession
SCN5A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10582
GenAtlas
SCN10A
GeneCards
SCN10A
GenBank Gene Database
AF117907
GenBank Protein Database
4838145
Guide to Pharmacology
585
UniProt Accession
SCNAA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1442
GeneCards
CALM1
UniProt Accession
CALM1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1445
GeneCards
CALM2
UniProt Accession
CALM2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1449
GeneCards
CALM3
UniProt Accession
CALM3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72